These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Research on the mechanism of prednisone in the treatment of ITP via VIP/PACAP-mediated intestinal immune dysfunction. Yan X; Zhang Y; Lang H; Huang Z; Chen X; He H; Zhao Q; Wang J Eur J Med Res; 2023 Feb; 28(1):67. PubMed ID: 36750876 [TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433 [TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression. Delgado M; Ganea D J Immunol; 2000 Feb; 164(3):1200-10. PubMed ID: 10640731 [TBL] [Abstract][Full Text] [Related]
7. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. Delgado M; Reduta A; Sharma V; Ganea D J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Delgado M; Ganea D J Immunol; 2000 Sep; 165(6):3051-7. PubMed ID: 10975815 [TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009 [TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Ganea D; Delgado M Crit Rev Oral Biol Med; 2002; 13(3):229-37. PubMed ID: 12090463 [TBL] [Abstract][Full Text] [Related]
11. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells. Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043 [TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Delgado M; Jonakait GM; Ganea D Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. Delgado M; Ganea D J Immunol; 2001 Jul; 167(2):966-75. PubMed ID: 11441105 [TBL] [Abstract][Full Text] [Related]
15. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP. Ganea D; Delgado M Arch Immunol Ther Exp (Warsz); 2001; 49(2):101-10. PubMed ID: 11348014 [TBL] [Abstract][Full Text] [Related]
16. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. Delgado M; Leceta J; Abad C; Martinez C; Ganea D; Gomariz RP J Neuroimmunol; 1999 Sep; 99(1):61-71. PubMed ID: 10496178 [TBL] [Abstract][Full Text] [Related]